Findings

What do systematic reviews say?

7 questions · 9 findings · 1 reviews · Dementia and Cognitive Improvement

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 55.6%Moderate 4 · 44.4%High 0 · 0%

Change in apathy · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 145 participants
Low
Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 85 participants
Low

Adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease

Methylphenidate showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
RR 1.28 [0.67, 2.42]
3 studies · 145 participants
Low

Change in NPS · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Change in cognition · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 145 participants
Moderate

Change in functional performance · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Moderate
Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Moderate

Change in global disease severity · Apathy in people with mild‐to‐moderate Alzheimer's disease

Methylphenidate showed no clear difference in change in global disease severity compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
RR 0.56 [0.15, 2.1]
2 studies · 85 participants
Moderate

Leaving the study early · Apathy in people with mild‐to‐moderate Alzheimer's disease

Methylphenidate showed no clear difference in dropouts compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for apathy in Alzheimer's disease 2018 · Cochrane Headline outcomes only
RR 2.1 [0.6, 7.38]
3 studies · 145 participants
Low